ABSTRACT
Amiodarone, considered a potent antiarrhythmic, is known to cause pulmonary toxicity. Chronic interstitial pneumonitis is the most common presentation. However, acute pulmonary toxicity is rare and has a higher case fatality rate. We present a 61-year-old patient with persistent atrial fibrillation who, after a one-month treatment with oral amiodarone at a low dose impregnation of 400 mg/day, develops acute pulmonary toxicity, with radiographic and tomographic resolution after antiarrhythmic suspension and steroid treatment.
Se sabe que la amiodarona, un potente antiarrítmico, causa toxicidad pulmonar. La neumonitis intersticial crónica es la presentación más común. Sin embargo, la toxicidad pulmonar aguda es rara y provoca una mayor mortalidad. Se presenta un paciente de 61 años con fibrilación auricular persistente que, tras tratamiento por un mes con amiodarona vía oral a dosis baja de impregnación de 400 miligramos al día, desarrolló toxicidad pulmonar aguda secundaria al antiarrítmico confirmada por radiografía y tomografía. Su caso tuvo resolución después de la suspensión del fármaco y tratamiento con esteroides.
Subject(s)
Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Lung Diseases/chemically induced , Acute Disease , Amiodarone/administration & dosage , Anti-Arrhythmia Agents/administration & dosage , Atrial Fibrillation/drug therapy , Dose-Response Relationship, Drug , Humans , Male , Middle AgedABSTRACT
Se sabe que la amiodarona, un potente antiarrítmico, causa toxicidad pulmonar. La neumonitis intersticial crónica es la presentación más común. Sin embargo, la toxicidad pulmonar aguda es rara y provoca una mayor mortalidad. Se presenta un paciente de 61 años con fibrilación auricular persistente que, tras tratamiento por un mes con amiodarona vía oral a dosis baja de impregnación de 400 miligramos al día, desarrolló toxicidad pulmonar aguda secundaria al antiarrítmico confirmada por radiografía y tomografía. Su caso tuvo resolución después de la suspensión del fármaco y tratamiento con esteroides.
Amiodarone, considered a potent antiarrhythmic, is known to cause pulmonary toxicity. Chronic interstitial pneumonitis is the most common presentation. However, acute pulmonary toxicity is rare and has a higher case fatality rate. We present a 61-year-old patient with persistent atrial fibrillation who, after a one-month treatment with oral amiodarone at a low dose impregnation of 400 mg/day, develops acute pulmonary toxicity, with radiographic and tomographic resolution after antiarrhythmic suspension and steroid treatment.
Subject(s)
Humans , Male , Middle Aged , Amiodarone/adverse effects , Lung Diseases/chemically induced , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/drug therapy , Acute Disease , Dose-Response Relationship, Drug , Amiodarone/administration & dosage , Anti-Arrhythmia Agents/administration & dosageABSTRACT
RESUMEN Introducción: En Cuba, los estudios descriptivos y experimentales que exploran los trastornos cardiovasculares secundarios a enfermedades neurológicas son escasos, tanto en el campo de la clínica como de la neurocardiología. Objetivos: Caracterizar los hallazgos electrocardiográficos en las primeras 72 horas de evolución de la enfermedad cerebrovascular y su relación con la mortalidad. Método: Se realizó un estudio observacional, descriptivo, de corte longitudinal prospectivo, en 166 pacientes ingresados en el Hospital Clínico-Quirúrgico Joaquín Albarrán, con el diagnóstico de enfermedad cerebrovascular de cualquier etiología y forma de presentación, durante el período de enero de 2015 a diciembre de 2016. Resultados: Los hallazgos electrocardiográficos estuvieron presentes en el 32,5% de los pacientes, fundamentalmente la taquicardia sinusal (27,7 %), la inversión de la onda T y las extrasístoles auriculares (13,3% cada uno). Se encontró una frecuencia significativamente mayor de cambios electrocardiográficos en los pacientes con hemorragia subaracnoidea (33,3% frente a 5,4%), menor puntuación en la escala de coma de Glasgow (29,7% frente a 5,4%) y localización a nivel de los ganglios basales (50,0%). La presencia de nuevos hallazgos electrocardiográficos se relacionó con una probabilidad 7,2 veces mayor de muerte intrahospitalaria (40,7% frente a 7,1%). Conclusiones: La presencia de nuevas alteraciones electrocardiográficas en pacientes con enfermedad cerebrovascular puede ser empleado como un marcador de riesgo de mortalidad intrahospitalaria.
ABSTRACT Introduction: In Cuba, descriptive and experimental studies that explore cardiovascular disorders secondary to neurological diseases are scarce, both in the clinical and neurocardiology fields. Objectives: To characterize the electrocardiographic findings in the first 72 hours of evolution of the cerebrovascular disease and its relation to mortality. Method: An observational, descriptive, longitudinal prospective study was carried out in 166 patients admitted to the Hospital Clínico-Quirúrgico Joaquín Albarrán, with the diagnosis of cerebrovascular disease of any etiology and form of presentation, during the period of January 2015 to December 2016. Results: Electrocardiographic findings were present in 32.5% of patients, mainly sinus tachycardia (27.7%), T wave inversion and premature atrial contractions (13.3% each). A significantly higher frequency of electrocardiographic changes was found in patients with subarachnoid hemorrhage (33.3% vs. 5.4%), lower score on the Glasgow coma scale (29.7% vs. 5.4%) and location at the level of the basal ganglia (50.0%). The presence of new electrocardiographic findings was related to a 7.2 times greater probability of in-hospital death (40.7% vs. 7.1%). Conclusions: The presence of new electrocardiographic alterations in patients with cerebrovascular disease can be used as a marker of risk of in-hospital mortality.
Subject(s)
Stroke , Arrhythmias, Cardiac , ElectrocardiographyABSTRACT
More than 6 billion people live outside industrialized countries and have insufficient access to cardiac surgery. Given the recently confirmed high prevailing mortality for rheumatic heart disease in many of these countries together with increasing numbers of patients needing interventions for lifestyle diseases due to an accelerating epidemiological transition, a significant need for cardiac surgery could be assumed. Yet, need estimates were largely based on extrapolated screening studies while true service levels remained unknown. A multi-author effort representing 16 high-, middle-, and low-income countries was undertaken to narrow the need assessment for cardiac surgery including rheumatic and lifestyle cardiac diseases as well as congenital heart disease on the basis of existing data deduction. Actual levels of cardiac surgery were determined in each of these countries on the basis of questionnaires, national databases, or annual reports of national societies. Need estimates range from 200 operations per million in low-income countries that are nonendemic for rheumatic heart disease to >1,000 operations per million in high-income countries representing the end of the epidemiological transition. Actually provided levels of cardiac surgery range from 0.5 per million in the assessed low- and lower-middle income countries (average 107 ± 113 per million; representing a population of 1.6 billion) to 500 in the upper-middle-income countries (average 270 ± 163 per million representing a population of 1.9 billion). By combining need estimates with the assessment of de facto provided levels of cardiac surgery, it emerged that a significant degree of underdelivery of often lifesaving open heart surgery does not only prevail in low-income countries but is also disturbingly high in middle-income countries.
